- Home
- ROIV vs FWONA Comparison
ROIV vs FWONA Comparison
Compare ROIV & FWONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | FWONA |
|---|---|---|
| Founded | 2014 | 1950 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Broadcasting |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 19.6B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ROIV | FWONA |
|---|---|---|
| Price | $29.41 | $82.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $27.56 | ★ $101.75 |
| AVG Volume (30 Days) | ★ 4.0M | 145.6K |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,053,000.00 | N/A |
| Revenue This Year | N/A | $24.56 |
| Revenue Next Year | $878.32 | $5.71 |
| P/E Ratio | ★ N/A | $97.75 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.01 | $73.70 |
| 52 Week High | $30.33 | $99.49 |
Technical Indicators
Market Signals| Indicator | ROIV | FWONA |
|---|---|---|
| Relative Strength Index (RSI) | 61.61 | 63.82 |
| Support Level | $20.46 | $75.29 |
| Resistance Level | $30.33 | $85.60 |
| Average True Range (ATR) | 0.87 | 1.90 |
| MACD | 0.14 | 0.66 |
| Stochastic Oscillator | 89.84 | 92.76 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About FWONA Liberty Media Corporation Series A Liberty Formula One
Liberty Media Corp along with its subsidiaries is engaged in the media and entertainment industries in North America and the United Kingdom. The company owns interests in a high-quality portfolio of assets across the media, entertainment and sports industries. The company derives its maximum revenue from United Kingdom.